SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2107884

Cover Image

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2107884

U.S. 503B Compounding Pharmacies Market, By Product Type (Sterile Compounded Drugs, Non-sterile Compounded Drugs), By Packaging (Vials, Prefilled Syringes, Ampoules, Syringes, Others), By Geography (U.S.)

PUBLISHED:
PAGES: 259 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4500
PDF & Excel (Multi User License - Up to 7 Users)
USD 7000
PDF & Excel (Corporate User License)
USD 10000

Add to Cart

U.S. 503B Compounding Pharmacies Market is estimated to be valued at USD 1,350 Mn in 2026 and is expected to reach USD 2,260 Mn by 2033, growing at a compound annual growth rate (CAGR) of 7.6% from 2026 to 2033.

Report Coverage Report Details
Base Year: 2025 Market Size in 2026: USD 1,350 Mn
Historical Data for: 2020 To 2024 Forecast Period: 2026 To 2033
Forecast Period 2026 to 2033 CAGR: 7.60% 2033 Value Projection: USD 2,260 Mn

These are specialized types of drug manufacturing organizations that serve a critical role in the patient care, as stated by the United States Pharmacopoeia (USP), compounding provides access to medication for patients who may not be able to use commercially available formulations due to dosing requirements, allergies, or rare diseases. The 503B compounding pharmacies are required to be registered with the U.S. FDA and maintain full compliance with the current good manufacturing practices (cGMP).

The cGMP guidelines compounding pharmacies needs to follow are 503B compounding pharmacies are must validate every process according to CGMP.

503B facilities must produce multiple batches and submit them for testing and stability before a new product can be brought to market.

503B products and testing methods must be validated according to US pharmacopeia (USP). Similarly, all suppliers and vendors providing raw materials must be evaluated. Moreover, onsite inspection must be performed by quality personnel.

Market Dynamics

The increasing launches of 503B compounding pharmacies in the U.S and increasing adoption of inorganic growth strategies such as mergers, acquisitions, partnerships, and collaborations by key players operating in the market are the major factors that are expected to drive growth of the U.S. 503B compounding pharmacies market over the forecast period.

For instance, in January 2022, Hikma Pharmaceuticals PLC, the multinational pharmaceutical company, announced the launch of Hikma 503B, a new outsourced sterile compounding business focused on providing high quality, ready to administer injectable medications that are customized to the specific need of patients in the U.S.

Key features of the study

  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the U.S. 503B compounding pharmacies market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Central Admixture Pharmacy Services, Inc., Nephron Pharmaceuticals Corporation, QuVa Pharma, Olympia Pharmacy, ASP Cares, Fagron Compounding Pharmacies, Athenex, Inc., Avella Specialty Pharmacy, Atlas Pharmaceuticals, Empower Pharmacy, Carie Boyd'S Prescription Shop, Edge Pharma, Imprimis NJOF, LLC, IntegraDose Compounding services, LLC, Wells Pharma of Houston, LLC, US Compounding Inc., and SCA Pharma
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The U.S 503B Compounding pharmacies market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. 503B compounding pharmacies market.

Market Segmentation

  • By Product Type (Revenue, USD Mn, 2021-2033)
  • Sterile Compounded Drugs
  • Non-sterile Compounded Drugs
  • By Packaging (Revenue, USD Mn, 2021-2033)
  • Vials
  • Prefilled Syringes
  • Ampoules
  • Syringes
  • Others
  • Key Players
  • Central Admixture Pharmacy Services, Inc.
  • Nephron Pharmaceuticals Corporation
  • QuVa Pharma
  • Olympia Pharmacy
  • ASP Cares
  • Fagron Compounding Pharmacies
  • Athenex, Inc.
  • Avella Specialty Pharmacy
  • Atlas Pharmaceuticals
  • Empower Pharmacy
  • Carie Boyd'S Prescription Shop
  • Edge Pharma
  • Imprimis NJOF, LLC
  • IntegraDose Compounding services, LLC
  • Wells Pharma of Houston, LLC
  • US Compounding Inc.
  • SCA Pharma
Product Code: CMI4481

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Product Type
    • Market Snapshot, By Packaging
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Product Approval
  • Collaboration/Merge/Acquisition
  • Regulatory Landscape
  • PEST Analysis
  • Porter's Five Forces Analysis
  • Epidemiology
  • Robust Pipeline Analysis

4. U.S. 503B Compounding Pharmacies Market, By Product Type, 2021 - 2033, (USD Million)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022- 2033
    • Segment Trends
  • Sterile Compounded Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
  • Non-sterile Compounded Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)

5. U.S. 503B Compounding Pharmacies Market, By Packaging, 2021 - 2033, (USD Million)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022 - 2033
    • Segment Trends
  • Vials
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
  • Prefilled Syringes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
  • Ampoules
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
  • Syringes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)

6. Competitive Landscape

  • Heat Map Analysis
  • Market Share Analysis
  • Company Profile
    • Central Admixture Pharmacy Services, Inc.
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
    • Nephron Pharmaceuticals Corporation
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
    • QuVa Pharma
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
    • Olympia Pharmacy
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
    • ASP Cares
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
    • Fagron Compounding Pharmacies
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
    • Athenex, Inc.
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
    • Avella Specialty Pharmacy
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
    • Atlas Pharmaceuticals
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
    • Empower Pharmacy
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
    • Carie Boyd'S Prescription Shop
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
    • Edge Pharma
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
    • Imprimis NJOF, LLC
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
    • IntegraDose Compounding services, LLC
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
    • Wells Pharma of Houston, LLC
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
    • US Compounding Inc.
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
    • SCA Pharma
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
  • Analyst Views

7. Section

  • References
  • Research Methodology
  • About Us
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!